In the global battle against cancer, the development of powerful new therapeutic agents has outpaced the ability to deliver them safely and effectively to tumors. For oncologists, pharmaceutical researchers, and healthcare executives, the central challenge is no longer solely about discovering active molecules—it is about ensuring these potent drugs reach their intended targets while sparing healthy tissues from toxicity. This is the domain of novel drug delivery systems (NDDS) for cancer therapy. These advanced technologies—ranging from drug-eluting beads and targeted microspheres to selective internal radiation therapy—are transforming how cancer treatments are administered, offering the promise of enhanced efficacy, reduced side effects, and improved quality of life for patients. According to comprehensive new analysis, the global market for these innovative delivery platforms is positioned for steady, value-driven expansion within the broader context of a dynamic pharmaceutical industry. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Novel Drug Delivery Systems for Cancer Therapy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032” . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Novel Drug Delivery Systems for Cancer Therapy market, including market size, share, demand, industry development status, and forecasts for the next few years.
The numbers reflect a mature but steadily growing market. The global market for Novel Drug Delivery Systems for Cancer Therapy was estimated to be worth US$ 6,753 million in 2024 and is forecast to reach a readjusted size of US$ 7,586 million by 2031, growing at a CAGR of 1.7% during the forecast period 2025-2031 . This steady, if modest, growth trajectory underscores the essential role these technologies play in modern oncology and their integration into standard treatment protocols.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
(https://www.qyresearch.com/reports/4033495/novel-drug-delivery-systems-for-cancer-therapy)
Defining Novel Drug Delivery Systems for Cancer Therapy: Precision Targeting of Tumors
Novel drug delivery systems for cancer therapy encompass a range of advanced technologies designed to deliver therapeutic agents directly to tumors or to control their release in the body, maximizing efficacy while minimizing systemic toxicity. Unlike conventional chemotherapy, which circulates throughout the body affecting both cancerous and healthy cells, these targeted systems aim to concentrate treatment at the disease site.
Key technologies in this field include:
- Embolization Particles – Drug Eluting Beads: These are microspheres loaded with chemotherapy drugs that are injected into arteries supplying blood to tumors. The beads block blood flow (embolization) while slowly releasing the drug, creating a dual therapeutic effect.
- Polyvinyl Alcohol Particles and Microspheres: Used primarily for embolization, these particles block blood vessels feeding tumors, starving them of nutrients.
- Gelatin-Based Embolization Devices: Temporary embolic agents that are eventually absorbed by the body, offering flexibility in treatment planning.
- Selective Internal Radiation Therapy (SIRT): This involves delivering microscopic radioactive spheres directly into the arteries supplying liver tumors, delivering high radiation doses to the tumor while sparing healthy liver tissue.
- Holmium-Based Microspheres: These are used both for treatment and imaging, enabling physicians to visualize the distribution of the microspheres and verify targeting.
- Liquid Embolics – Onyx: A liquid embolic agent that solidifies upon contact with blood, used to block blood vessels feeding tumors, particularly in the brain.
These technologies are primarily used in hospitals and clinics by interventional radiologists and oncologists specializing in minimally invasive cancer treatments.
The Broader Pharmaceutical Market Context
To understand the position of novel drug delivery systems in oncology, it is essential to view them within the context of the global pharmaceutical market. The global pharmaceutical market was valued at approximately US$ 1,475 billion in 2022, with projections for continued growth at a CAGR of about 5% over the following years. This vast market encompasses both chemical drugs and biological drugs.
Biological drugs represent a rapidly growing segment, with the market expected to reach approximately US$ 381 billion in 2022. Biologics, including monoclonal antibodies and cell therapies, are increasingly important in cancer treatment and often require specialized delivery systems.
The chemical drug market, while more mature, remains substantial, estimated to increase from US$ 1,005 billion in 2018 to US$ 1,094 billion in 2022. Many novel drug delivery systems are designed to improve the therapeutic index of established and new chemical entities.
Key factors driving the broader pharmaceutical market include:
- Increasing demand for healthcare globally
- Technological advancements in drug discovery and development
- Rising prevalence of chronic diseases, including cancer
- Increased funding from private and government organizations for pharmaceutical manufacturing and R&D
However, the industry faces significant challenges, including stringent regulatory requirements, high costs of research and development, and patent expirations that expose blockbuster drugs to generic competition. Companies must continuously innovate and adapt to stay competitive and ensure their products reach patients in need.
The COVID-19 pandemic added another layer of complexity, highlighting the critical importance of vaccine development speed, supply chain resilience, and the ability of pharmaceutical companies to respond rapidly to emerging public health needs. These lessons are shaping strategic planning across the industry, including in oncology drug delivery.
Market Dynamics and Growth Factors
The projected 1.7% CAGR for novel drug delivery systems in cancer therapy, while modest compared to some high-growth technology sectors, reflects several important market dynamics.
Steady Clinical Adoption: These technologies have become integrated into standard treatment protocols for certain cancers, particularly liver cancer and metastases. Their adoption is driven by clinical evidence demonstrating improved outcomes and reduced side effects compared to systemic therapies.
Aging Population and Cancer Incidence: The global aging population continues to drive cancer incidence, creating sustained demand for all cancer therapies, including advanced delivery systems.
Trend Toward Minimally Invasive Treatments: Patients and physicians increasingly prefer minimally invasive procedures that offer shorter recovery times and fewer side effects. Interventional oncology procedures using drug delivery systems align with this preference.
Innovation in Materials and Formulations: Ongoing research into new materials—such as biodegradable polymers, novel radionuclides, and combination products—is expanding the capabilities and applications of drug delivery systems.
Expanding Indications: Researchers are exploring the use of these technologies in additional cancer types beyond liver cancer, potentially expanding the addressable market.
Market Challenges
Despite their clinical value, novel drug delivery systems face several challenges that contribute to the modest growth rate.
Regulatory Hurdles: As combination products (device + drug/radiation source), these systems face complex regulatory pathways requiring expertise in both pharmaceutical and medical device regulation.
High Development Costs: Bringing a new drug delivery system to market requires substantial investment in materials science, preclinical testing, clinical trials, and manufacturing scale-up.
Reimbursement and Pricing Pressures: Healthcare systems worldwide are under cost-containment pressure, and novel technologies must demonstrate clear value to secure favorable reimbursement.
Competition from Systemic Therapies: Advances in systemic therapies, including immunotherapies and targeted agents, continue to improve outcomes and may compete with localized delivery approaches for some indications.
Specialized Expertise Required: These procedures require specialized training and equipment, limiting their availability to major medical centers and potentially slowing adoption.
Competitive Landscape: Specialists and Medical Device Leaders
The novel drug delivery systems for cancer therapy market features a mix of specialized interventional oncology companies and larger medical device manufacturers with oncology portfolios. Key players identified in the QYResearch report include Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc (now part of Boston Scientific), CeloNova BioSciences, Inc. , Cook Medical, Inc. , Cospheric LLC, Covidien, plc (now part of Medtronic), Eckert & Ziegler BEBIG, EmboMedics, Inc. , Kobo Products, Inc. , Merit Medical Systems, Inc. , Mo-Sci Corporation, Nanobiotix, Polysciences, Inc. , Sirtex Medical, Inc. (now part of CDH Investments), and Terumo Corporation .
Boston Scientific Corporation is a major player in interventional medicine, with a portfolio including drug-eluting beads and embolization technologies. BTG plc, acquired by Boston Scientific, brought complementary technologies including TheraSphere for selective internal radiation therapy.
Sirtex Medical, Inc. is a leader in selective internal radiation therapy with its SIR-Spheres microspheres, widely used for liver cancer treatment. Terumo Corporation is a global medical device company with significant presence in interventional oncology.
Cook Medical, Inc. and Merit Medical Systems, Inc. are established players in interventional devices, including embolization products. Eckert & Ziegler BEBIG specializes in brachytherapy and radiation oncology products.
Nanobiotix represents the emerging field of nanomedicine, developing nanoparticles designed to enhance radiation therapy.
This diverse competitive landscape reflects the convergence of pharmaceutical science, materials engineering, and medical device manufacturing in the field of interventional oncology.
Exclusive Industry Observation: The Process Manufacturing Model and Quality Imperative
A critical observation for the novel drug delivery systems industry is its reliance on process manufacturing rather than discrete assembly. Many of these products—microspheres, nanoparticles, embolic agents—are produced through continuous chemical or physical processes that require precise control over formulation, particle size distribution, and quality attributes. This process orientation demands expertise in chemistry, materials science, and pharmaceutical manufacturing that differs significantly from traditional medical device assembly.
The quality imperative in this field is absolute. Products intended for intravascular administration or direct tumor injection must meet stringent standards for sterility, consistency, and performance. Manufacturing processes must be validated and controlled to ensure every dose meets specifications. Regulatory inspections of manufacturing facilities are rigorous, and any quality lapse can have severe consequences for patients and companies.
This manufacturing complexity creates barriers to entry and favors established players with deep expertise and validated production capabilities. It also creates opportunities for contract manufacturing organizations with specialized capabilities in sterile pharmaceutical manufacturing and particle engineering.
Strategic Implications for Decision-Makers
For pharmaceutical and medical device executives, novel drug delivery systems represent opportunities to extend product lifecycles, differentiate offerings, and address unmet medical needs. Partnerships between drug developers and delivery system specialists can accelerate development and combine complementary expertise.
For hospital administrators and interventional oncologists, staying current with advances in drug delivery technology is essential for offering patients the full range of treatment options. Investment in training and equipment enables delivery of these advanced procedures.
For investors, the novel drug delivery systems market offers exposure to a stable, clinically essential segment of the oncology landscape. Companies with strong technology positions, robust quality systems, and established relationships with healthcare providers are well-positioned in this specialized market.
As cancer treatment continues to evolve toward more personalized, targeted approaches, the technologies that enable precise delivery of therapy will remain essential. The 1.7% CAGR projected through 2031 reflects the steady, essential role these systems play in the broader oncology armamentarium.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
